{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|frameless|upright=0.3|center]]
|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
*[[Ewing's sarcoma]]
*[[Osteosarcoma]]
</big>
=Guidelines=
==[http://www.esmo.org/ ESMO]==
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]

=Chondrosarcoma, all lines of therapy=
*No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
*Mesenchymal chondrosarcoma has been treated with [[Ewing's sarcoma|Ewing's sarcoma regimens]]
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]

=Giant-cell tumor of bone, all lines of therapy=
==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f50a28|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010]
|style="background-color:#91cf61"|Phase II
|-
|}
====Primary therapy====
*[[Denosumab (Xgeva)]] as follows:
**Cycle 1: 120 mg SC once per day on days 1, 8, 15 
**Cycle 2 onwards: 120 mg SC once on day 1

====Supportive medications====
*Calcium 500 mg PO once per day
*Vitamin D 400 IU PO once per day

'''28-day cycles, given until complete tumor resection, progression of disease, or patient choice'''

===References===
# Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed]

=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy=
*Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]

[[Category:Bone sarcoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Bone sarcomas]]
